IKE Tech Files First-Ever PMTA for Standalone Interoperable Blockchain-based Age-Gating System at Point of Use - Marking a New Chapter in Youth Vaping Prevention
LOS ANGELES, May 1, 2025 /PRNewswire/ -- IKE Tech LLC('IKE Tech'), a leading innovator in the intersection of Internet of Things (IoT), identity verification (IDV) and tokenization technology, announced today that it has filed a component Premarket Tobacco Product Application (PMTA) and Tobacco Product Master File (TPMF) with the US Food and Drug Administration (FDA) for its blockchain-based Bluetooth Low Energy (BLE) System-on-a-Chip with the smartphone-enabled identity and age-verification IKE Mobile Application.
This marks the first ever complete PMTA submission for a standalone, scalable age-gating component that provides real-time continuous age verification at the point-of-use for electronic nicotine delivery systems (ENDS). The IKE System is designed for universal integration across all ENDS devices, utilizing unique blockchain-based tokenization technology to further ensure user privacy and security.
According to a multi-center Human Factors Validation Study submitted as part of the PMTA, the IKE system proved to be 100% effective in preventing device activation for anyone under the age of 21. The company has formally requested expedited review of its application, emphasizing the system's potential to enhance public health.
'This is a major milestone for IKE Tech and the ENDS category', commented John Patterson, President of IKE Tech. 'We're not just building technology. We're paving a new regulatory framework that gives the FDA and manufacturers powerful tools to safeguard public health and ensure adult-only access to vaping products. With proven, scalable age-gating technology built into ENDS devices, the sector now has a real opportunity to eliminate underage vaping for good'.
One chip, every device: unlocking new era of vaping
IKE Tech adopted a rigorous software development lifecycle, following consultation with the FDA. The IKE platform offers a seamless identity and age verification experience via a single, user-friendly mobile app available on iOS and Android. By leveraging blockchain technology, it securely validates user's identity and age through integrated identity verification (IDV) partners, anchoring credentials to a tokenization system without storing sensitive data on user's device, nor on IKE's system, to ensure complete user privacy and security.
Unlike existing solutions that allow permanent access after a single verification, IKE's system requires continuous verification to maintain device access. Human Factors Validation study showed 91% of users (aged 18 – 67) rated the app as 'Extremely Easy' or 'Very Easy' to use - with a user error rate of less than 0.8% - proving its appeal to the wider market.
'This is a pivotal moment from a regulatory perspective,' said Kevin Burd, CEO of Chemular. By embedding robust age verification at the point of use, the IKE technology enables manufacturers and regulators to confidently allow access to a broader range of products for verified adults. This approach opens the doors for responsible flavor pathways, empowering adult consumers with more choice, while maintaining the highest levels of youth protection.'
Building Smarter and Better ENDS
IKE Tech is dedicated to building a better, more secure future for all. To meet the evolving needs of manufacturers, the company is planning to continue integrating advanced features like counterfeit protection, geofencing, targeted messaging, and real-time data access to its systems.
These innovations are designed to address underage vaping and combat the illicit market, ensuring that only products that FDA has determined are Appropriate for the Protection of Public Health (APPH) are available to adult users.
To learn more about IKE Tech, visit www.iketech.com.
Notes to Editors:
Human Factors Study Design and Key Results
Conducted with 102 participants (51% male, 49% female, aged 18–67 across race/ethnic demographics), the study simulated real-world use of the IKE system. Participants downloaded the app, verified their age, paired with a test device and interacted with BLE-based access controls including biometric reactivation.
Key performance highlights:
Devices could only be reactivated with biometric authentication. Demographic data (age, race/ethnicity, gender) was accurately verified in all cases. The results confirm the IKE System's ability to reduce user error, prevent underage access, and provide a user-friendly experience for adults.
About IKE Tech
IKE Tech LLC ('IKE Tech') is pioneering real-time age and identity verification at the point of use, helping to safeguard access to age-restricted products.
A leading innovator at the intersection of Internet of Things (IoT), identity verification (IDV), and tokenization technology, IKE Tech has developed an industry-first, scalable age-gating component that provides continuous, real-time verification for electronic nicotine delivery systems (ENDS) and other restricted consumer products.
IKE Tech's interoperable Bluetooth Low Energy (BLE) System-on-a-Chip, powered by a user-friendly mobile app available on iOS and Android, integrates seamlessly into ENDS devices, giving manufacturers and regulators a flexible, future-proofed solution to combat underage vaping and illicit markets. By setting the new standard for responsible, adult-only access, IKE Tech is helping eliminate youth vaping for good.
View original content: https://www.prnewswire.com/news-releases/ike-tech-files-first-ever-pmta-for-standalone-interoperable-blockchain-based-age-gating-system-at-point-of-use---marking-a-new-chapter-in-youth-vaping-prevention-302443438.html
SOURCE IKE Tech LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
12 hours ago
- The Hill
Food and Drug Administration staff cuts may hinder US biomedical innovation
President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.
Yahoo
12 hours ago
- Yahoo
Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength
GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies? The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength. Before: AI-Powered Foresight for Accurate Market Opportunity Detection AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning. Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification. AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas. Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit. End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product. During: Efficient Execution to Deliver Outstanding Products Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams. Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays. Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements. Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time. Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste. Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts. AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge. Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response. Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation. Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D. Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis. Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks. After: Data-Driven Innovation Strategy Optimization Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance. Deeper Insights: Identify key factors that influence project success. Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration. Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product. Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation. Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility. The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape. We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster! Website: Email：Marketing@ View original content: SOURCE Cyberway Information Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Chocolate company recalls product nationwide for undeclared allergen
NEW YORK (PIX11) — Chocolate products have been recalled nationwide due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. The Pennsylvania-based distributor, Weaver Nut Company, Inc., has recalled its semi-sweet chocolate nonpareils with white or Christmas colored seeds, the advisory from the FDA says. More Local News People who have an allergy or severe sensitivity to milk could face serious or life-threatening allergic reactions if they consume the impacted products, the FDA warns. So far no illnesses have been reported. The issue was discovered through a wholesale customer who filed a complaint saying the shipment was misaligned with the product specifications. Lab tests confirmed the presence of milk in the product. More: Latest News from Around the Tri-State Consumers who have purchased the recalled product are urged not to eat it if they have a milk allergy and return it to the place of purchase for a full refund. Below is the list of lot codes for the affected chocolates. 47518 – Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) 204206 204207 204208 204209 204212 224225 D2645 – Nonpareils, Semi-Sweet Chocolate (White Seeds) 204214-RL 204214 204215 224221 224222 224223 135215 135216 135217 135220 135221 145204 145205-1 145207-1 145210-1 Dominique Jack is a digital content producer from Brooklyn with more than five years of experience covering news. She joined PIX11 in 2024. More of her work can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
